---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001376"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:55:28.121940+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Chromocell authorizes $250K stock repurchase plan; up to ~23% of non-affiliate float

## Summary
- Authorized repurchase of up to $250,000 of common stock, representing ~23% of non-affiliate float.
- Repurchases may occur via open market or private transactions through Dec 31, 2024.
- CEO states stock price does not reflect progress in developing non-opioid pain treatments.
- Plan does not obligate company to repurchase any shares; may be modified or terminated.

## SEC filing metadata
- accession: 0001753926-24-001376
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392624001376/0001753926-24-001376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392624001376/g084379_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001376
- JSON: https://secwatch.observer/filing/0001753926-24-001376.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001376.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.